1333 related articles for article (PubMed ID: 28298208)
1. Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.
Chen LK; Arai H; Chen LY; Chou MY; Djauzi S; Dong B; Kojima T; Kwon KT; Leong HN; Leung EM; Liang CK; Liu X; Mathai D; Pan JY; Peng LN; Poblete ER; Poi PJ; Reid S; Tantawichien T; Won CW
BMC Infect Dis; 2017 Mar; 17(1):213. PubMed ID: 28298208
[TBL] [Abstract][Full Text] [Related]
2. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
Oh H; Tan C; Williams C; Giannelos N; Ng C
Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
[TBL] [Abstract][Full Text] [Related]
3. A systematic literature review of the epidemiology and burden of herpes zoster in selected locales in Asia Pacific.
Chen J; Abrahamson PE; Ke Y; Ong CR; Parikh R; Shantakumar S
Hum Vaccin Immunother; 2024 Dec; 20(1):2344983. PubMed ID: 38767209
[TBL] [Abstract][Full Text] [Related]
4. Vaccination against herpes zoster in developed countries: state of the evidence.
Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
[TBL] [Abstract][Full Text] [Related]
5. Vaccination: a new option to reduce the burden of herpes zoster.
Mick G
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
[TBL] [Abstract][Full Text] [Related]
6. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
8. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
Hoshi SL; Kondo M; Okubo I
Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
[TBL] [Abstract][Full Text] [Related]
10. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
Betts RF
J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866
[TBL] [Abstract][Full Text] [Related]
11. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
13. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Herpes Zoster Vaccine for Persons Aged 50 Years.
Le P; Rothberg MB
Ann Intern Med; 2015 Oct; 163(7):489-97. PubMed ID: 26344036
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
16. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
[TBL] [Abstract][Full Text] [Related]
17. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
Annemans L; Bresse X; Gobbo C; Papageorgiou M
J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
[TBL] [Abstract][Full Text] [Related]
18. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Weidemann F; Reinhold T; Siedler A; Krause G; Wichmann O
BMC Health Serv Res; 2013 Sep; 13():359. PubMed ID: 24070414
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America.
Araújo LQ; Macintyre CR; Vujacich C
Herpes; 2007 Sep; 14 Suppl 2():40-4. PubMed ID: 17939895
[TBL] [Abstract][Full Text] [Related]
20. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.
Langan SM; Smeeth L; Margolis DJ; Thomas SL
PLoS Med; 2013; 10(4):e1001420. PubMed ID: 23585738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
